Compare NetApp Inc. (NTAP) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetApp Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? NetApp Inc. trades at $237.19 (market cap $45.38B), while State Street SPDR S&P Biotech ETF trades at $153.85 (market cap $10.11B). The key difference: NetApp Inc. is far larger — about 4.5× State Street SPDR S&P Biotech ETF's market cap, and NetApp Inc. pays a 0.9% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold NetApp Inc. for 56 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| NTAP | XBI | |
|---|---|---|
Market Cap | $45.38B | $10.11B |
Volume | 2,264,311 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $235.84 | $169.55 |
52-Week Low | $94.11 | $104.99 |
Typical Hold Time | 56 Days | 38 Days |
Enterprise Value | $44.34B | — |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetApp (NTAP) trades at $237.15, up 0.56% today, with strong technical momentum as the stock approaches resistance near $239. The company demonstrates robust fundamentals with a 70.63% gross margin and consistent earnings beats, including Q2 2026 EPS of $2.58 beating expectations by 21.7%. Recent AI infrastructure partnerships with Oracle and Supermicro position NTAP for growth in enterprise data storage markets.
While valuation metrics appear elevated with a P/E of 32.63, the company's AI-driven growth strategy and strong profitability support upside potential. Key risks include competitive pressures in cloud storage and potential margin compression. Analyst consensus remains mixed with 38% buy ratings but a $219.30 price target below current levels, suggesting cautious optimism.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
